Revisiting IBS: Recrafting the Diagnosis for More Timely Treatment and Patient-Centered CarePremiere Date: Thursday, June 9, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, June 9, 2023
|William D. Chey, MD, AGAF, FACG, FACP (Moderator)
Timothy T. Nostrant Collegiate Professor of Gastroenterology
Professor of Nutrition Sciences
Chief, Division of Gastroenterology & Hepatology
Departments of Internal Medicine and Nutritional Sciences
University of Michigan
Ann Arbor, MI
|Lin Chang, MD
Professor of Medicine
Vice-Chief, Vatche and Tamar Manoukian Division of Digestive Diseases
Co-Director, G. Oppenheimer Center for Neurobiology of Stress and Resilience
David Geffen School of Medicine at UCLA
Los Angeles, CA
|Amy Ladewski, PA-C, RD, MMS
Digestive Health Center
Northwestern Memorial Hospital
Despite being one of the most commonly encountered conditions in primary care and gastroenterology practices, an overwhelming number of patients with irritable bowel syndrome (IBS) remain undiagnosed. Misdiagnosis, misunderstanding, and a lack of patient-centered care alienate patients with IBS who are seeking support, guidance, and treatment. Newly published American College of Gastroenterology guidelines for diagnosing and treating patients with IBS exist but are not routinely implemented, resulting in diagnostic delays. There is a need for strategies to improve diagnostic accuracy, familiarization with efficacious and safe IBS therapies, and patient-centered care, including shared decision-making (SDM), education, and patient-reported outcomes (PROs).
This live CME Outfitters symposium will feature an expert panel discussion crafted with a focus on patients with IBS that provides strategies for obtaining accurate diagnosis, presents new and emerging clinical data on the efficacy and safety of IBS therapies, and details approaches for patient-centered care to achieve optimal outcomes.
At the end of this CE activity, participants should be able to:
- Implement strategies to improve diagnostic accuracy of IBS through the use of patient queries and diagnostic tools.
- Recognize efficacy and safety of IBS therapies to inform treatment decision-making.
- Implement approaches for patient-centered care for IBS, such as SDM, education, and PROs.
Supported by educational grants from AbbVie Inc. and Ironwood Pharmaceuticals, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in gastroenterology and/or primary care
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Chey reports the following financial relationships:
Consultant: AbbVie Inc; Alnylam Pharmaceuticals Inc.; Arena Pharmaceuticals, Inc.; Biomerica, Inc.; Covita; Everlywell, Inc.; Gemelli Biotech; IM Health; Ironwood Pharmaceuticals, Inc.; ISOThrive Inc.; Nestle; Phathom Pharmaceuticals; Progenity, Inc.; QOL Medical; RedHill Biopharma Inc.; Salix Pharmaceuticals/Valeant Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; Urovant Sciences, Inc.; and Vibrant Pharma Inc.
Research Support: Biomerica, Inc.; Commonwealth Diagnostics International, Inc.; U.S. Food and Drug Administration (FDA); National Institutes of Health (NIH); QOL Medical; and Salix Pharmaceuticals
Stock Shareholder (directly purchased): Options: Options: GI OnDEMAND; ISOThrive Inc.; and ModifyHealth, LLC
Other: Patents: Digital Manometry; Nutrition Health; and Rectal Expulsion Device
Dr. Chang reports the following financial relationships:
Advisory Board: Ardelyx; Arena Pharmaceuticals, Inc.; Cosmo Pharmaceuticals; Immunic Therapeutics; Ironwood Pharmaceuticals, Inc.; Mauna Kea Technologies; and Protagonist Therapeutics Inc.
Consultant: Trellus, Inc.
Research Support: AnX Robotica; Arena Pharmaceuticals, Inc.; Ironwood Pharmaceuticals, Inc.; and Vanda Pharmaceuticals
Speakers Bureau: AbbVie Inc.
Stock Shareholder (ownership interest): ModifyHealth, LLC and Trellus, Inc.
Ms. Ladewski reports the following financial relationships:
Advisory Board: Mahana Therapeutics, Inc. and Phathom Pharmaceuticals
Consultant: Ironwood Pharmaceuticals, Inc. and Salix Pharmaceuticals
Speakers Bureau: Salix Pharmaceuticals and Takeda Pharmaceuticals U.S.A., Inc.
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).